Physician profile
David A Galli
NPI 1255323374
$2,423.00
in general payments reported to CMS, 2019-2025
27 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $158 · 2021: $435 · 2022: $695 · 2023: $255 · 2024: $248 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Gift: $750 · Food and Beverage: $22.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Gift | $750.00 |
| Food and Beverage | $22.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sekisui Diagnostics LLC | $1,310.00 | 2022-2025 | |
| Abbvie INC. | $176.06 | 2021-2024 | |
| Novo Nordisk INC | $105.78 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $99.57 | 2019-2021 | |
| Pfizer INC. | $97.65 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $89.41 | 2019-2022 | |
| Janssen Biotech, INC. | $70.49 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $48.62 | 2021-2022 | |
| Amarin Pharma, INC. | $46.99 | 2019-2021 | |
| Lilly USA, LLC | $39.08 | 2019-2021 | |
| Lundbeck LLC | $37.89 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.24 | 2021 | |
| Amgen INC. | $34.80 | 2019-2021 | |
| Sanofi Pasteur INC. | $28.86 | 2019-2021 | |
| Glaxosmithkline, LLC. | $24.83 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $19.64 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.86 | 2019 | |
| Pacira Therapeutics, INC. | $16.36 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.79 | 2020 | |
| Eisai INC. | $15.63 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.60 | 2021 | |
| Merck Sharp & Dohme LLC | $14.41 | 2021 | |
| Ge Healthcare | $14.36 | 2019 | |
| Endo Pharmaceuticals INC. | $13.21 | 2020 | |
| Astellas Pharma US INC | $13.11 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.69 | 2019 | |
| Zyla Life Sciences, INC. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Galli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.